Sunitinib, a multi-kinase inhibitor targeting PDGFR, VEGFR, KIT, and fms-like tyrosine kinase 3 (FLT-3), yielded unsatisfactory results compared with sorafenib in patients with advanced HCC. Here, KDR is linked to hepatocellular carcinoma.